Experts are rapidly investigating retatrutide, a innovative medication developed by Eli Lilly, as a significant breakthrough in body loss . Unlike many earlier approaches, retatrutide is a dual -action agonist targeting both GLP-1 and GIP, chemicals that influence appetite and glucose control . Ini